Emcure Pharmaceuticals announced strong Q3FY26 results, reporting a 20.4% year-over-year increase in revenue, reaching Rs 2,363Cr. Profit after tax grew by 48%. The domestic business grew by 15.4%, while international business surged by 24.5%. The company launched Poviztra®, a biological injectable form of semaglutide, in India. Emcure’s Board also re-appointed independent directors, pending member approval.
Financial Performance
Emcure Pharmaceuticals reported robust financial results for Q3FY26. Key highlights include:
- Revenue from operations: Rs 2,363Cr (up 20.4% YoY)
- EBITDA: Margins at 19.5%, with EBITDA at Rs 460Cr (up 27.2% YoY)
- PAT: Rs 231Cr (up 48.2% YoY), including an exceptional expense of Rs 38Cr related to labour code changes
- Domestic Business: Sales at Rs 1,025Cr (up 15.4% YoY)
- International Business: Sales at Rs 1,338Cr (up 24.5% YoY)
The company launched Poviztra®, a biological injectable form of semaglutide, in India, positioning Emcure in the weight management segment. International business growth was strong at 24.5%, with all geographies contributing.
Segmental Revenue Breakdown
The revenue from operations can be broken down as follows:
- Domestic: Rs 1,025Cr (up 15.4% YoY)
- International: Rs 1,338Cr (up 24.5% YoY)
- RoW: Rs 477Cr (up 30.7% YoY)
- EU: Rs 464Cr (up 29.6% YoY)
- Canada: Rs 397Cr (up 12.8% YoY)
Re-appointment of Independent Directors
The Board of Directors approved the re-appointment of the following Independent Directors for a second consecutive term, subject to member approval:
- Dr. Shailesh Kripalu Ayyangar (effective June 02, 2026)
- Mr. Vijay Keshav Gokhale (effective April 16, 2026)
- Dr. Vidya Rajiv Yeravdekar (effective April 16, 2026)
Company Secretary Appointment
Ms. Amruta Jana Yangalwar has been appointed as Company Secretary and Compliance Officer.
Postal Ballot Approval
A postal ballot will be conducted to seek member approval for the re-appointment of Independent Directors.
Source: BSE
